 |
|
Off-label Prescribing Among Office-Based Physicians
David C. Radley, MPH;
Stan N. Finkelstein, MD;
Randall S. Stafford, MD, PhD
Arch Intern Med. 2006;166:1021-1026.
Background Unlike medicines prescribed for Food and Drug Administration–approved indications, off-label uses may lack rigorous scientific scrutiny. Despite concerns about patient safety and costs to the health care system, little is known about the frequency of off-label drug use or the degree of scientific evidence supporting this practice.
Methods We used nationally representative data from the 2001 IMS Health National Disease and Therapeutic Index (NDTI) to define prescribing patterns by diagnosis for 160 commonly prescribed drugs. Each reported drug-diagnosis combination was identified as Food and Drug Administration–approved, off-label with strong scientific support, or off-label with limited or no scientific support. Outcome measures included (1) the proportion of uses that were off-label and (2) the proportion of off-label uses supported by strong scientific evidence. Multivariate analyses were used to identify drug-specific characteristics predictive of increased off-label use.
Results In 2001, there were an estimated 150 million (95% confidence interval, 127-173 million) off-label mentions (21% of overall use) among the sampled medications. Off-label use was most common among cardiac medications (46%, excluding antihyperlipidemic and antihypertensive agents) and anticonvulsants (46%), whereas gabapentin (83%) and amitriptyline hydrochloride (81%) had the greatest proportion of off-label use among specific medications. Most off-label drug mentions (73%; 95% confidence interval, 61%-84%) had little or no scientific support. Although several functional classes were associated with increased off-label use (P<.05), few other drug characteristics predicted off-label prescription.
Conclusions Off-label medication use is common in outpatient care, and most occurs without scientific support. Efforts should be made to scrutinize underevaluated off-label prescribing that compromises patient safety or represents wasteful medication use.
Author Affiliations: Center for Evaluative Clinical Sciences, Dartmouth Medical School, Hanover, NH (Mr Radley); Program on the Pharmaceutical Industry, Sloan School of Management, Massachusetts Institute of Technology, Cambridge (Dr Finkelstein); and Program on Prevention Outcomes and Practices, Stanford Prevention Research Center, Stanford, Calif (Dr Stafford). Dr Finkelstein is now additionally with Harvard Medical School, Boston, Mass.
RELATED LETTER
Positive Outcomes Through the Appropriate Use of Off-Label Prescribing
Jennifer L. Bright
Arch Intern Med. 2006;166(22):2554-2555.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cardiac Resynchronization Therapy for Heart Failure: A Hammer in Search of Nails
McAlister
Circulation 2008;118:901-903.
FULL TEXT
Who Are the New Users of Antipsychotic Medications?
Domino and Swartz
Psychiatr. Serv. 2008;59:507-514.
ABSTRACT
| FULL TEXT
FDA Guidance on Off-Label Promotion and the State of the Literature From Sponsors
Psaty and Ray
JAMA 2008;299:1949-1951.
FULL TEXT
Pharmaceutical Promotion to Physicians and First Amendment Rights
Kesselheim and Avorn
NEJM 2008;358:1727-1732.
FULL TEXT
Regulating Off-Label Drug Use -- Rethinking the Role of the FDA
Stafford
NEJM 2008;358:1427-1429.
FULL TEXT
Gabapentin: a multimodal perioperative drug?
Kong and Irwin
Br J Anaesth 2007;99:775-786.
ABSTRACT
| FULL TEXT
Indication creep: physician beware
Hebert and Stanbrook
CMAJ 2007;177:697-697.
FULL TEXT
L'expansion des indications : medecins, attention
Hebert and Stanbrook
CMAJ 2007;177:699-699.
FULL TEXT
What Cannot Be Said on Television About Health Care
Emanuel
JAMA 2007;297:2131-2133.
FULL TEXT
Positive Outcomes Through the Appropriate Use of Off-Label Prescribing
Bright
Arch Intern Med 2006;166:2554-2555.
FULL TEXT
Safeguarding Patient Welfare: Who's In Charge?
Henney
ANN INTERN MED 2006;145:305-307.
FULL TEXT
|
